Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group.

Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. Review.

2.

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM.

Alzheimers Dement (N Y). 2019 Jan 23;5:20-26. doi: 10.1016/j.trci.2018.11.001. eCollection 2019.

3.

The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology.

Cahill MA, Jazayeri JA, Catalano SM, Toyokuni S, Kovacevic Z, Richardson DR.

Biochim Biophys Acta. 2016 Dec;1866(2):339-349. doi: 10.1016/j.bbcan.2016.07.004. Epub 2016 Jul 22. Review.

PMID:
27452206
4.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111899. doi: 10.1371/journal.pone.0111899. eCollection 2014.

5.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.

6.

Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluations using the International Programme on Chemical Safety framework.

Da Rocha MS, Arnold LL, De Oliveira ML, Catalano SM, Cardoso AP, Pontes MG, Ferrucio B, Dodmane PR, Cohen SM, De Camargo JL.

Crit Rev Toxicol. 2014 May;44(5):393-406. doi: 10.3109/10408444.2013.877870. Epub 2014 Feb 11. Review.

PMID:
24512549
7.

Discovery and development of an aurora kinase inhibitor clinical candidate using an image-based assay for measuring proliferation, apoptosis, and DNA content.

Catalano SM, McLaughlin J, Hitoshi Y, Payan D.

Assay Drug Dev Technol. 2009 Apr;7(2):180-90. doi: 10.1089/adt.2007.086.

PMID:
19505233
8.

Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.

Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, Igoudin L, Hironaka CM, Lowe RM, McEntee M, Ruslim-Litrus L, Wu HM, Zhang S, Catalano SM, Goure WF, Summa D, Krafft GA.

Curr Alzheimer Res. 2007 Dec;4(5):562-7. Review.

PMID:
18220523
9.

The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease.

Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG.

Curr Top Med Chem. 2006;6(6):597-608. Review.

PMID:
16712494
10.

Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library.

Hitoshi Y, Gururaja T, Pearsall DM, Lang W, Sharma P, Huang B, Catalano SM, McLaughlin J, Pali E, Peelle B, Vialard J, Janicot M, Wouters W, Luyten W, Bennett MK, Anderson DC, Payan DG, Lorens JB, Bogenberger J, Demo S.

Chem Biol. 2003 Oct;10(10):975-87. No abstract available.

PMID:
14583264
11.

Netrin-1 promotes thalamic axon growth and is required for proper development of the thalamocortical projection.

Braisted JE, Catalano SM, Stimac R, Kennedy TE, Tessier-Lavigne M, Shatz CJ, O'Leary DD.

J Neurosci. 2000 Aug 1;20(15):5792-801.

12.

Activity-dependent cortical target selection by thalamic axons.

Catalano SM, Shatz CJ.

Science. 1998 Jul 24;281(5376):559-62.

13.

Many major CNS axon projections develop normally in the absence of semaphorin III.

Catalano SM, Messersmith EK, Goodman CS, Shatz CJ, Ch├ędotal A.

Mol Cell Neurosci. 1998 Jul;11(4):173-82.

PMID:
9675049
14.

Activity-dependent regulation of NMDAR1 immunoreactivity in the developing visual cortex.

Catalano SM, Chang CK, Shatz CJ.

J Neurosci. 1997 Nov 1;17(21):8376-90.

15.

Individual axon morphology and thalamocortical topography in developing rat somatosensory cortex.

Catalano SM, Robertson RT, Killackey HP.

J Comp Neurol. 1996 Mar 25;367(1):36-53.

PMID:
8867282
16.

Rapid alteration of thalamocortical axon morphology follows peripheral damage in the neonatal rat.

Catalano SM, Robertson RT, Killackey HP.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2549-52.

17.

Early ingrowth of thalamocortical afferents to the neocortex of the prenatal rat.

Catalano SM, Robertson RT, Killackey HP.

Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):2999-3003.

18.

Early climbing fiber interactions with Purkinje cells in the postnatal mouse cerebellum.

Mason CA, Christakos S, Catalano SM.

J Comp Neurol. 1990 Jul 1;297(1):77-90.

PMID:
1695909
19.

Field application of the conditioned taste aversion paradigm to the control of coyote predation on sheep and turkeys.

Ellins SR, Catalano SM.

Behav Neural Biol. 1980 Aug;29(4):532-6. No abstract available.

PMID:
7447856

Supplemental Content

Loading ...
Support Center